In contrast to the anti-PD-1-based therapies and in line with previous reports on breast cancer [50, 51], anti-CTLA-4 monotherapy did not result in a therapeutic benefit in MC1 PDXs (Additional file 4: Figure S3). Here, CTLA4 is linked to breast carcinoma.